Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials-Reference-Cited by-同舟云学术

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

Published:2013-07-28 Issue:1 Volume:16 Page:38-47
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Monami M.¹,Dicembrini I.²,Nardini C.¹,Fiordelli I.²,Mannucci E.²

Affiliation:

1. Geriatric Cardiology; Careggi Teaching Hospital; Florence Italy

2. Diabetes Agency; Careggi Teaching Hospital; Florence Italy

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12175/fullpdf

Reference25 articles.

1. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials;Monami;Eur J Endocrinol,2009

2. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis;Monami;Exp Diabetes Res,2012

3. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials;Vilsbøll;BMJ,2012

4. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials;Wang;Diabetes Obes Metab,2013

5. Chilton R Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers;Chiquette;Vasc Health Risk Manag,2012

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group;Diabetes Therapy;2024-07-11

2. Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection;Canadian Journal of Cardiology;2023-12

3. Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes;IJC Heart & Vasculature;2023-08

4. The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance;Journal of Diabetes and its Complications;2023-08

5. Eco-friendly chitosan-based nanostructures in diabetes mellitus therapy: Promising bioplatforms with versatile therapeutic perspectives;Environmental Research;2023-07